Detalhe da pesquisa
1.
Adjuvant treatment for locally advanced gastric cancer: an Asian perspective.
Gastric Cancer
; 27(3): 439-450, 2024 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38489111
2.
Factors associated with the efficacy of first-line nivolumab plus chemotherapy in advanced gastric cancer patients with deficient mismatch repair.
Gastric Cancer
; 2024 May 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38780852
3.
SMARCA4-deficient undifferentiated gastric carcinoma: a case series and literature review.
Gastric Cancer
; 2024 May 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38772975
4.
DNA mismatch repair deficiency and outcomes of patients with locally advanced gastric cancer treated with preoperative docetaxel, oxaliplatin, and S-1 plus surgery and postoperative S-1 or surgery plus postoperative S-1: a sub-analysis of the phase 3 PRODIGY trial.
Gastric Cancer
; 27(1): 110-117, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37889360
5.
Discordant PD-L1 results between 28-8 and 22C3 assays are associated with outcomes of gastric cancer patients treated with nivolumab plus chemotherapy.
Gastric Cancer
; 2024 Apr 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38647978
6.
Clinical outcomes of Epstein-Barr virus (EBV)-associated metastatic and locally advanced unresectable gastric cancers (GCs) in patients receiving first-line fluoropyrimidine and platinum (FP) doublet chemotherapy.
Gastric Cancer
; 27(1): 146-154, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38006567
7.
Prognostic value of mismatch repair deficiency in patients receiving first-line fluoropyrimidine plus platinum for metastatic, recurrent, or unresectable gastric cancer.
Gastric Cancer
; 2024 Mar 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-38555561
8.
Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an international, randomized, placebo-controlled, phase 3 trial.
Gastric Cancer
; 27(2): 375-386, 2024 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38281295
9.
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial.
Lancet Oncol
; 24(11): 1181-1195, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37875143
10.
A randomised phase 2 study of continuous or intermittent dosing schedule of imatinib re-challenge in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumours.
Br J Cancer
; 129(2): 275-282, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37179439
11.
AZD8186 in Combination With Paclitaxel in Patients With Advanced Gastric Cancer: Results From a Phase Ib/II Study (KCSG ST18-20).
Oncologist
; 28(9): e823-e834, 2023 09 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37036671
12.
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.
N Engl J Med
; 382(25): 2419-2430, 2020 06 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-32469182
13.
Interruption of imatinib in advanced gastrointestinal stromal tumor after prolonged imatinib maintenance in the absence of gross tumor lesions.
Gastric Cancer
; 26(4): 604-613, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36884149
14.
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 23(2): 234-247, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35030335
15.
Clinical outcomes and prognostic factors for patients with high-risk gastrointestinal stromal tumors treated with 3-year adjuvant imatinib.
Int J Cancer
; 151(10): 1770-1777, 2022 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35678337
16.
Prognostic value of natural killer cell activity for patients with HER2 + advanced gastric cancer treated with first-line fluoropyrimidine-platinum doublet plus trastuzumab.
Cancer Immunol Immunother
; 71(4): 829-838, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-34420059
17.
Predictive biomarkers for the efficacy of nivolumab as ≥ 3rd-line therapy in patients with advanced gastric cancer: a subset analysis of ATTRACTION-2 phase III trial.
BMC Cancer
; 22(1): 378, 2022 Apr 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35397540
18.
Insertion-deletion rate is a qualitative aspect of the tumor mutation burden associated with the clinical outcomes of gastric cancer patients treated with nivolumab.
Gastric Cancer
; 25(1): 226-234, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34468871
19.
Association between HER2 heterogeneity and clinical outcomes of HER2-positive gastric cancer patients treated with trastuzumab.
Gastric Cancer
; 25(4): 794-803, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35524883
20.
Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial.
Gastric Cancer
; 25(1): 197-206, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34468869